INT

Brazil
Brazil

Time filter

Source Type

PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people.  This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people.  This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


PARIS, May 11, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat ageing diseases, has announced that it has received the approval from the US regulatory authorities for the recruitment of sarcopenia patients in the observational study SARA-OBS on Sarconeos. It has therefore been able to open the two clinical centers and start the recruitment of sarcopenia patients in the United States. These patients, if they give their consent, could participate in the clinical trial of phase 2b SARA-INT, on Sarconeos. Stanislas Veillet, Chief Executive Officer of BIOPHYTIS, said: “We are delighted to announce the recruitment of the first patient in the SARA-OBS clinical study in the United States. The US clinical centers of Boston and Gainesville are now open and recruiting patients. These centers are specialized in sarcopenia patients care, led by internationally renowned clinicians, and ideally complete our European clinical network. It marks an important step of our development strategy in the US, our primary market, which was announced one year ago. We are now focusing on the preparation of the interventional phase, SARA-INT, which will follow on this observational study.” BIOPHYTIS has obtained the authorization of the regulatory authorities to start the SARA-OBS clinical study in sarcopenia. The first two clinical centers have therefore been opened, in Boston at the Jean Mayer Human Nutrition Research Center on Aging, Tufts University with head investigator Professor Roger Fielding, and in Gainesville at the Institute of Aging, University of Florida, with investigator Professor Marco Pahor. The recruitment of the 300 patients in the 8 clinical centers opened in Europe (France, Belgium and Italy) and the United States has now begun. Sarcopenia patients will be monitored for 6 months before being possibly included in the interventional phase 2b SARA-INT study, after obtaining their consent. The opening of centers in the United States is a critical marker of the development strategy initiated a year ago. It consists in a doubling of the size of the clinical study by recruiting patients in the US (the most important market for BIOPHYTIS in terms of number of patients), opening of a subsidiary in Boston, recruitment of reputable clinicians, in particular Roger A Fielding who joined BIOPHYTIS’ Scientific Advisory Board, and is the head researcher of the SARA-OBS/SARA-INT study. To know more about the SARA clinical program and Sarcopenia, you may also watch the introductory video by following this link: http://www.biophytis.com/en/actualites/SARA-ICFSR-2017/ About SARA-OBS: SARA-OBS is a 6-months clinical observational study, conducted in over 300 sarcopenia patients recruited in 8 clinical centers in Europe and the United States. Patients’ mobility and muscular quality will be assessed, based on the following criteria: 6-minute walk test, mobility (SPPB test), muscle strength (grip test), body composition and plasmatic parameters. Data from SARA-OBS will provide a better characterization of the target population for the Sarconeos treatment. Patients in the SARA-OBS study will be included in the phase 2b study of SARA-INT at the end of 6 months, once consent is given. ABOUT SARCONEOS: Sarconeos is the first representative of a new class of drug candidates, based on the activation of the MAS receptor (major player of the renin-angiotensin system) stimulating anabolism in the muscle, inhibitor of myostatin and favoring muscle mass development in animal models of muscular dystrophies. Sarconeos is developed in the treatment of sarcopenia, an age-related degeneration of skeletal muscle and strength, leading to a loss of mobility in elderly people.  This new pathology, for which no medical treatment currently exists, was first described in 1993 and just entered the WHO International Classification of Diseases (M62.84), affects more than 50 million people worldwide. About BIOPHYTIS: BIOPHYTIS SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, BIOPHYTIS has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical need. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD). The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute. BIOPHYTIS is listed on the Alternext market of Euronext Paris (ALBPS; ISIN: FR0012816825). BIOPHYTIS is eligible for the SMEs scheme Disclaimer This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Alternext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS’ website (www.biophytis.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in 5 both French and English. In the event of any differences between the two texts, the French language version shall supersede.


Warner Bros.' The Lego Batman Movie earned the most nominations of any film by title with 11 followed by 9 nominations each for Disney's Guardians of the Galaxy Vol 2, and Lionsgate's La La Land. Top trailer houses in this year's pack included Mark Woollen & Associates with 33 nominations, AV Squad with 29 noms, and Trailer Park with 28. On the agency side, LA was the leading creative print house for their work on 34 nominees. The Golden Trailer Awards are presented live on stage to nominees in diverse categories that range from serious to lighthearted, including Best Summer 2017 Blockbuster Trailer, Trashiest Trailer, Best of Show, and the most popular award of the night: the Golden Fleece Award, bestowed on the best trailer for the film where the marketing was considered better than the film itself. Explained Watters, "Trailers, commercials and posters are a true and unique art form and the Golden Trailer Awards celebrate the artists and editors who work tirelessly behind the scenes to create these amazing marketing materials. This year's nominees represent the best-of-the-best of the year in film and television marketing. We love the outstanding caliber of the creativity and are honored to once again shine a light on this special part of the industry." 17 of the top honors are presented "live" on stage at the celebratory show, which routinely sells out and draws a heavy industry crowd of studio and network marketing executives, representatives from creative agencies, media and celebrities. This year's competition drew a record number of submissions, up nearly 50% from last year's total. In total, Golden Trailer Awards are presented to winners across 116 diverse categories. Last year, more than 1,100 studio marketing executives, movie fans, celebrities and trailer editors were on hand to celebrate as Open Road Films & Insync Plus' trailer for the film "Spotlight" took home top honors as the Best of Show. For more information, tickets to the show, or to download the full list of nominations, please visit www.goldentrailer.com When on social media, please use #goldentrailer18 Best Action Baby Driver, "Burn Out", Sony Pictures International, Create Advertising London John Wick: Chapter 2, "Vengeance", Lionsgate, AV Squad King Arthur: Legend of the Sword, "Throne", Warner Brothers, Open Road Entertainment Kong: Skull Island, "Magnificent", Warner Bros., Trailer Park, Inc. Passengers, "INT'L Trailer G", Sony Pictures, Project X/AV Best Animation / Family A Dog's Purpose,  "Life", Universal Pictures, InSync PLUS Beauty and the Beast, "Tale", Disney, Aspect Despicable Me 3, "Brothers", Universal Pictures, Motive Creative The Lego Batman Movie, "Domestic Trailer", Warner Bros. Entertainment Inc., Rogue Planet The Lego Batman Movie, "ComicCon", Warner Bros. Pictures, Transit Best Comedy Bad Moms, "Play Date Red", STX Entertainment, Trailer Park, Inc. Baywatch, "Domestic Trailer 2", Paramount Pictures, Workshop Creative Office Christmas Party, "Ho Ho Ho", Paramount, Industry Creative Snatched, "Non-Refundable", 20th Century Fox, AV Squad The House, "Bets", Warner Brothers, mOcean Best Documentary I Am Not Your Negro, Trailer, Magnolia Pictures, Mark Woollen & Associates Rats, "Rats", Discovery, Warrior Poets Risk, "Risk", Neon Rated, Jump Cut Tickled, "Everywhere", Magnolia Pictures, Zealot Weiner, Trailer, IFC Films, Mark Woollen & Associates Best Drama Dunkirk, "Home", Warner Bros., Buddha Jones Hidden Figures, "Trailer C", Fox, Giaronomo Productions Moonlight, A24, Mark Woollen & Associates Patriots Day, "Survive", CBS Films, Aspect Sully, "Brace", Warner Bros, Ignition Best Fantasy Adventure Doctor Strange, "Future", Disney / Marvel, mOcean Fantastic Beasts and Where to Find Them, Trailer, Warner Bros., Mob Scene Miss Peregrine's Home for Peculiar Children, "Protect", 20th Century Fox, Wild Card Rogue One: A Star Wars Story, "Protect", Walt Disney Studios, AV Squad Wonder Woman, "What She Is", Warner Brothers, Open Road Entertainment Best Horror Annabelle 2, "Pray", New Line Cinema, Buddha Jones Get Out, "Mind", Universal Pictures, Inside Job IT, "Slide", New Line Cinema, Buddha Jones The Conjuring 2, "Back", New Line Cinema, Buddha Jones The Hatred, "Alice", Anchor Bay, Lionsgate Best Independent Trailer Christine, "True Story", The Orchard, InSync PLUS Manchester By The Sea, Roadside Attractions, Mark Woollen & Associates The Birth of a Nation, Fox Searchlight, Mark Woollen & Associates The Book of Henry, "Trailer 1", Focus Features, AV Squad The Wall, "Survival", Amazon Studios, mOcean Best Music Atomic Blonde, "Online", Universal/Focus, AV Squad Guardians of the Galaxy Vol. 2, "Smile", Disney / Marvel, mOcean Logan, "Teaser", 20th Century Fox, Rogue Planet Sing, "Dream On", Universal Pictures, Motive Creative Thor: Ragnarok, "New Age", Disney / Marvel, mOcean Best Summer 2017 Blockbuster Trailer Atomic Blonde, "Online", Universal/Focus, AV Squad Guardians of the Galaxy Vol. 2, "Smile", Disney / Marvel, mOcean The Mummy, "Adventure", Universal, Wild Card Transformers, "Beautiful", Paramount Pictures, Rogue Planet Wonder Woman, "Darkness", Warner Bros., Trailer Park, Inc. Best Teaser American Assassin, "Faces", CBS Films, Big Picture Blade Runner: 2049, "Trailer 1", Warner Bros., Wild Card Dunkirk, "Imminent", Warner Bros., Trailer Park, Inc. La La Land, "City of Stars" Teaser, Lionsgate, Mark Woollen & Associates The Magnificent Seven, "Seven", Sony, AV Squad Best Thriller A Cure for Wellness, "Ghost Story", 20th Century Fox, Trailer Park, Inc. Arrival, "Journey", Sony, Wild Card Nerve, "Survive", Lionsgate, Seismic Productions Split, "Crack", Universal Pictures, Buddha Jones The Girl on the Train, "Heartless", Universal, Wild Card Golden Fleece Resident Evil: The Final Chapter, "Last Humanity", Sony Pictures Entertainment, Trailer Park, Inc. Sleepless, "Corrupt", Open Road Films , Big Picture The Disappointments Room, "Unlock the Secret", Relativity Europa, Buddha Jones The Sea of Trees, A24, Mark Woollen & Associates XXX: Return of Xander Cage, "Back Up", Paramount Pictures, Trailer Park, Inc. Most Original Trailer Atomic Blonde, "Seductress", Focus Features / NBC Universal, Jax La La Land, "Ultimate Encore" Trailer, Lionsgate, Tiny Hero Swiss Army Man, A24, Mark Woollen & Associates The Lego Batman Movie, "Gotham Cribs", Warner Bros. Pictures, Transit The Nice Guys, "70s Trailer", Warner Bros, Big Picture Trashiest Trailer Bad Santa 2, "Redband Trailer", Broad Green, Seismic Productions Bad Santa 2, "Naughty", Broad Green Pictures, mOcean Careful What You Wish For, "Hurts So Good" Trailer, Starz Digital, Zealot King Cobra, "Good Boy", IFC Midnight, Zealot Mike And Dave Need Wedding Dates, "Let Loose Red Band", Fox, Buddha Jones ### Above Presented On Stage on June 6th along with Best of Show Award ### Best Independent Trailer (for film budget shot under a million US) Alien Arrival, "Trailer", Vertical Entertainment, Shawn Stevens Deep Water: The Real Story, "Official Trailer", Black Fella Films, The Trace House Kicks, Focus World, Mark Woollen & Associates Spookers, "Spookers Theatrical Trailer", Madman Productions, Ben Holmes Temps, "Find", Grandex Productions/FilmBuff, Open Road Entertainment Best Motion/Title Graphics Atomic Blonde, "Online", Universal/Focus , AV Squad Baby Driver, "Baby", Sony Pictures Entertainment, Trailer Park, Inc. Thor: Ragnarok, "New Age", "New Age", Disney / Marvel, mOcean Three Billboards Outside Ebbing, Missouri, "Red Band Trailer", Fox Searchlight, Motive Creative War for the Planet of the Apes, "Snow", 20th Century Fox, Wild Card Best Romance Complete Unknown, "Past" Trailer, IFC Films, Zealot La La Land, "Triumph", Lionsgate, Seismic Productions Song to Song, Broad Green Pictures, Mark Woollen & Associates The Light Between Oceans, DreamWorks, Mark Woollen & Associates The Promise, "Love", Survival Pictures, Industry Creative Best Original Score Beauty and the Beast, "Tale" Final Trailer, Disney, Aspect King Arthur: Legend of the Sword, "Story", Warner Bros., Wild Card La La Land, "City of Stars" Teaser, Lionsgate, Mark Woollen & Associates Moonlight, Trailer, A24, Mark Woollen & Associates Popstar: Never Stop Never Stopping, "Never Stop", Universal, AV Squad Best Sound Editing Alien: Covenant, "Theirs", 20th Century Fox, Wild Card Atomic Blonde, "Online", Universal/Focus, AV Squad Deepwater Horizon, "Monster" Teaser, Lionsgate, Trailer Park King Arthur: Legend of the Sword, "Story", Warner Bros., Wild Card Kong: Skull Island, "Magnificent", Warner Bros., Trailer Park, Inc. Best Trailer - No Movie Fucking Heroes, "Red Band Trailer", Behind the Epic, Vadzim Khudabets Silent Night, "Secret", Fox, Seismic Productions The Kill Team, "Kill Team", Cornerstone, Intermission Film Toru, "Witness", A24 Films, GrandSon Best Video Game Trailer Call of Duty: Infinite Warfare, "Story Trailer", Activision, gnet Call of Duty: Modern Warfare Remastered, "Launch Trailer", Activision, gnet Dead Rising 4, "Twas the Night Before" Launch Trailer, Microsoft Xbox, gnet Dishonored 2, "Gameplay Launch Trailer", Bethesda Softworks, gnet The Witcher 3: Wild Hunt - Blood and Wine, "New Region" Trailer, Hammer Creative The Don LaFontane Award for Best Voice Over 20th Century Women, "Crisis" Teaser, A24, Mark Woollen & Associates I Am Not Your Negro, Magnolia Pictures, Mark Woollen & Associates The Shallows, "The Beginning", Sony, Concept Arts The Witch, "Twice", A24, AV Squad Voyage of Time, "International Trailer", Broad Green Pictures, Mark Woollen & Associates Best Foreign Action Trailer Collide, "Collide", Universum Film, Trailerhaus GmbH, Headshot, "Revenge" Trailer, Vertical Entertainment, Zealot Stegman Is Dead, "FU

Loading INT collaborators
Loading INT collaborators